EVA Tx is the new name for EpiVax Therapeutics (EVT) resulting from the establishment of a new majority shareholder, @GAIA Vaccine Foundation.  EVA Therapeutics aims to become a global leader in computational vaccine design for LMIC-focused diseases, accelerating solutions for neglected pathogens and supporting equitable vaccine access worldwide. 

Over time, EVA (an acronym for Equitable Vaccine Access) will build a pipeline of affordable, scalable vaccine candidates ready for downstream partners to manufacture and distribute in LMIC markets.

EVA Therapeutics

Org chart

Teams

Offices